Search Videos and More
Video
ASCO26: Alicia Morgans, MD, MPH, ARACOG
Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.
Video
ASCO26: Michael Hassett, MD, MPH, eSyM
Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.
Video
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Video
ESMO Breast Cancer 2026 Highlights: SERENA-6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: TRAK-ER
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: Saci-IO HR+
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.
Symposium
Breast Cancer Breakthroughs: ESMO 2026 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO26 in Berlin, Germany, including what the data means, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.
News
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology
The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.
News
Dana-Farber Researcher Selected to Join the Pew Scholars Program
The Pew Charitable Trusts announced that Xin Gu, PhD, of Dana-Farber Cancer Institute, is among 21 researchers who have been selected to join the Pew Scholars Program in the Biomedical Sciences.